Nalgesic (Fenoprofen Calcium)

Fenoprofen calcium works by non‑selectively blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for prostaglandin production. Lower prostaglandin levels lead to reduced inflammation, pain signaling, and fever responses in the affected tissues.

The specific dose of Nalgesic is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for fenoprofen calcium in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Fenoprofen calcium has a similar mechanism to other non‑selective NSAIDs such as ibuprofen, but it may offer a longer half‑life and different potency for certain inflammatory conditions. Choice of NSAID depends on individual patient response, safety profile, and physician preference.

Nalgesic should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and heat sources to maintain its stability and potency.

Nalgesic is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food may reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include gastrointestinal ulceration or bleeding, renal impairment, hepatic dysfunction, severe hypersensitivity reactions such as anaphylaxis, and increased cardiovascular events. Patients should be monitored for these adverse effects, especially during long‑term therapy.

Nalgesic should be avoided in individuals with known hypersensitivity to fenoprofen or other NSAIDs, active gastrointestinal ulceration, severe renal or hepatic impairment, and in patients taking anticoagulants where bleeding risk is unacceptable, unless directed by a physician.